Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19
Status:
Withdrawn
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs,
producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may
suffer from acute respiratory distress syndrome due to pneumonia (COVID-19 disease). Given
the high transmission, this virus has spread in recent months from Wuhan (China) to the whole
world, becoming a global emergency pandemic. The lack of curative treatment for this disease
justifies the need to carry out clinical trials that provide quality evidence on treatment
options. Given the pathophysiology of the disease, which involves an uncontrolled
inflammatory response of alveolar cells, a treatment that attenuates the cytokine cascade
could be key in rescuing the patient's lung tissue. Mesenchymal cells, due to their
immunoregulatory potential and regenerative capacity, can be an effective treatment for
patients infected with the SARS-CoV-2 virus.
In the present study we propose a therapy with undifferentiated allogeneic mesenchymal cells
derived from umbilical cord tissue, a treatment whose safety has already been described in
other clinical trials and that shows promising results in pilot studies carried out in China.